Cargando…
The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis
There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were retrospectively analyzed. Patients who received at...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535138/ https://www.ncbi.nlm.nih.gov/pubmed/34677260 http://dx.doi.org/10.3390/curroncol28050342 |
_version_ | 1784587706440876032 |
---|---|
author | Lakkunarajah, Suganija Breadner, Daniel A. Zhang, Hanbo Yamanaka, Ellen Warner, Andrew Welch, Stephen |
author_facet | Lakkunarajah, Suganija Breadner, Daniel A. Zhang, Hanbo Yamanaka, Ellen Warner, Andrew Welch, Stephen |
author_sort | Lakkunarajah, Suganija |
collection | PubMed |
description | There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were retrospectively analyzed. Patients who received at least 6 weeks of adjuvant therapy were included. The primary objective was to assess the influence of dose index (DI) and relative dose intensity (RDI) on DFS and OS at 3 and 5 years in patients receiving fluorouracil-based doublet therapy with oxaliplatin (FOLFOX) (5-FU and oxaliplatin assessed separately), or capecitabine monotherapy. In the capecitabine group, DFS rates for 3 and 5 years were 66.7% and 57.6%, respectively, while OS rates were 80.3% and 66.7%, respectively. Those who received FOLFOX had DFS rates of 76.9% and 71.2% at 3 and 5 years, respectively. OS rates were 86.4% and 76.7% at 3 and 5 years, respectively. Median RDI was 73.8% for capecitabine and 76.3% and 85.6% for the oxaliplatin and 5-FU components respectively. Based on a multivariate analysis in patients receiving FOLFOX, those with an oxaliplatin DI > 80% had improvements in DFS and OS compared to those with an oxaliplatin DI of ≤80%. Otherwise, there was no significant difference in DFS or OS when comparing patients who achieved an RDI or a DI of above versus below 80% in the patients receiving adjuvant chemotherapy for resected colon cancer. |
format | Online Article Text |
id | pubmed-8535138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85351382021-10-23 The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis Lakkunarajah, Suganija Breadner, Daniel A. Zhang, Hanbo Yamanaka, Ellen Warner, Andrew Welch, Stephen Curr Oncol Article There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were retrospectively analyzed. Patients who received at least 6 weeks of adjuvant therapy were included. The primary objective was to assess the influence of dose index (DI) and relative dose intensity (RDI) on DFS and OS at 3 and 5 years in patients receiving fluorouracil-based doublet therapy with oxaliplatin (FOLFOX) (5-FU and oxaliplatin assessed separately), or capecitabine monotherapy. In the capecitabine group, DFS rates for 3 and 5 years were 66.7% and 57.6%, respectively, while OS rates were 80.3% and 66.7%, respectively. Those who received FOLFOX had DFS rates of 76.9% and 71.2% at 3 and 5 years, respectively. OS rates were 86.4% and 76.7% at 3 and 5 years, respectively. Median RDI was 73.8% for capecitabine and 76.3% and 85.6% for the oxaliplatin and 5-FU components respectively. Based on a multivariate analysis in patients receiving FOLFOX, those with an oxaliplatin DI > 80% had improvements in DFS and OS compared to those with an oxaliplatin DI of ≤80%. Otherwise, there was no significant difference in DFS or OS when comparing patients who achieved an RDI or a DI of above versus below 80% in the patients receiving adjuvant chemotherapy for resected colon cancer. MDPI 2021-10-09 /pmc/articles/PMC8535138/ /pubmed/34677260 http://dx.doi.org/10.3390/curroncol28050342 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lakkunarajah, Suganija Breadner, Daniel A. Zhang, Hanbo Yamanaka, Ellen Warner, Andrew Welch, Stephen The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis |
title | The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis |
title_full | The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis |
title_fullStr | The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis |
title_full_unstemmed | The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis |
title_short | The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis |
title_sort | influence of adjuvant chemotherapy dose intensity on five-year outcomes in resected colon cancer: a single centre retrospective analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535138/ https://www.ncbi.nlm.nih.gov/pubmed/34677260 http://dx.doi.org/10.3390/curroncol28050342 |
work_keys_str_mv | AT lakkunarajahsuganija theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis AT breadnerdaniela theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis AT zhanghanbo theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis AT yamanakaellen theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis AT warnerandrew theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis AT welchstephen theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis AT lakkunarajahsuganija influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis AT breadnerdaniela influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis AT zhanghanbo influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis AT yamanakaellen influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis AT warnerandrew influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis AT welchstephen influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis |